A High: We are confident that the true effect lies close to that of the estimate of the effect.
Note: We recommend that serum creatinine (Cr) value (mg/dL) should be evaluated by the enzymatic assay method and rounded off to 2 decimal places. The Japanese GFR equation is applicable to adults aged 18 years or older.
CQ 1-2: How can we evaluate the severity of CKD? Statement: We recommend that CKD severity should be evaluated by cause, GFR category, and degree of proteinuria/ 1 3 CQ5: Is it recommended to treat metabolic acidosis of CKD patients to prevent deterioration of renal function? Statement: We recommend treating metabolic acidosis with sodium bicarbonate and other such bases to prevent hypertension, proteinuria, and CVD. It is recommended to consider treatment when a patient's HCO 3 -is below 21 mmol/L. Table 2 In case of CKD with heart failure (HFrEF) antihypertensive drugs and may suppress progression to mortality, onset of CVD and progression of renal dysfunction. However, to avoid the risk of AKI, it is necessary to adjust the dose carefully starting with a low dose and checking the serum Cr and K levels approximately 2 weeks after start. A RAS inhibitor is not used in principle when bilateral renal artery stenosis is suspected. (Level: C, Grade: 2) CQ3: Which imaging studies are recommended for CKD (Stage G1-3) with suspected renal artery stenosis? Statement: We suggest performing renal artery ultrasound as a screening test first, followed by plain MR angiography. When CT angiography and gadolinium-enhanced MR angiography are performed, the risk of contrast-induced nephropathy and nephrogenic systemic fibrosis must be considered carefully. When these tests do not lead to a diagnosis or when the indication of angioplasty is considered, we suggest performing renal artery angiography. Statement: We propose that the target Hb range for prescribing ESA to non-dialysis CKD patients is 11 g/dL or more and below 13 g/dL. In case of ESA hypo-responsiveness, determining the cause and correcting it are mandatory. Attention should be paid to avoiding over-dosage of ESA. Statement: In non-dialysis CKD patients with hyperphosphatemia, the administration of non-calcium-containing phosphate binders may be considered because they are potentially more effective in preventing progression to mortality and vascular calcification progression compared to calcium-containing phosphate binders (Level: C, Grade: 2).
CQ3: Is administration of active vitamin D recommended in non-dialysis CKD patients?
Statement: In non-dialysis CKD patients, administration of active vitamin D may be considered because it lowers PTH levels and may reduce proteinuria. However, active vitamin D can cause hypercalcemia and it is unknown whether this therapy decreases the risk of CKD progression, fracture, cardiovascular events, or mortality. Thus, we suggest therapeutic decisions be made on a case-by-case basis and active vitamin D be started with small doses. We also suggest that, in the case of hypercalcemia or worsening renal function, active vitamin D should be reduced or stopped promptly. (Level: C, Grade: 2) CQ4: Is administration of anti-osteoporotic agents recommended in non-dialysis CKD patients? Statement: In non-dialysis CKD patients, administration of anti-osteoporotic agents, such as active vitamin D, bisphosphonates, selective estrogen receptor modulators (SERMs), teriparatide, and denosumab may be considered because these may reduce fracture risk. Special attention, however, needs to be paid during treatment in CKD patients, because, depending on the agent, the expected beneficial and adverse effects may differ from those observed in the general population. Statement: Lipid-lowering therapy with statins or statins plus ezetimibe is recommended for patients with CKD and dyslipidemia, because it may potentially inhibit the development and recurrence of CVD events, reduce urinary protein excretion, and slow progression of renal dysfunction (Level: B Grade: 2). Meanwhile, lipid-lowering therapy with fibrates also could be useful for preventing development and recurrence of CVD events in those patients; however, we should use them carefully because fibrates are contraindicated or necessitate to be administered carefully in patients with moderate to severe renal dysfunction (Level: D, Grade: None).
Chapter 9. Management of metabolic syndrome
CQ1: Are obesity and metabolic syndrome risk factors of mortality, CVD, ESKD, and progression of CKD in patients with CKD? Statement: Metabolic syndrome is potentially associated with mortality, CVD, ESKD, and progression of CKD in patients with CKD, although obesity is not obviously associated with these outcomes. (Level: C, Grade: None) CQ2: Is exercise training recommended for CKD patients with obesity and/or metabolic syndrome? Statement: We suggest that CKD patients with obesity and/ or metabolic syndrome follow an aerobic exercise training program, which is effective for weight loss and improvement of peak oxygen consumption (VO 2 peak). Considering the clinical characteristics of each patient, the adequate load of aerobic exercise training should be estimated carefully. Statement: As management of CKD-MBD for pediatric patients with CKD may improve bone lesions and cardiovascular function, we recommend that it should be implemented. We suggest that the corrected serum levels of calcium and phosphorus should be maintained within normal ranges in accordance with patient age. (Level: C, Grade: 2) CQ9: Is administration of recombinant human growth hormone (rhGH) recommended for pediatric patients with CKD showing growth stunting? Statement: We suggest that rhGH administration should be considered for pediatric CKD patients with growth stunting as it can significantly increase the height of patients. (Level: A, Grade: 2) CQ10: Is preemptive kidney transplantation (PEKT) recommended for pediatric patients with CKD? Statement: We suggested that preemptive kidney transplantation should be considered for pediatric patients with CKD, as the likelihood of graft survival is higher than that after dialysis has been implemented. (Level: C, Grade: 2)
Chapter 12. Management of elderly CKD
Preamble: Renal replacement therapy (RRT) for elderly CKD patients aged more than 75 years In elderly CKD patients aged more than 75 years, an improvement in life prognosis by RRT can be expected. It is important to consult with nephrologists/special medical institutions when choosing RRT. The selection should be based on appropriate decision-making through discussion with the patients and their families by comprehensive consideration through the evaluation of renal function, medical history, multiple complications (CVD, malignant neoplasms, advanced dementia, severe frailty, and other), the patient's social situation, and anticipated life expectancy. In addition, understanding and practice of an appropriate preservation therapy and palliative care are required when the patients decide to forgo hemodialysis.
CQ1: Is treatment for CKD-MBD recommended for the elderly (≥ 75 years) CKD patients?
Statement: In elderly patients (aged 75 years or more) with non-dialysis CKD, we suggest limiting dietary phosphate intake and/or using phosphate binders to maintain serum phosphate levels within the normal range. In this population, close monitoring for adverse effects is required to prevent malnutrition since the phosphate-lowering therapies may cause loss of appetite. (Level: C, Grade: 2)
In elderly non-dialysis CKD patients with secondary hyperparathyroidism, we suggest lowering parathyroid hormone levels within the normal range by treating abnormalities in serum phosphate and calcium levels before administering active vitamin D agents. Hypercalcemia must be avoided when using active vitamin D agents. (Level: C, Grade: 2) CQ2: Can intervention in elderly CKD patients aged more than 75 years, prevent or control the progression of frailty, improve life prognosis, prolong induction of renal replacement therapy? Statement: In elderly CKD patients aged more than 75 years, frailty is one of the indicators of renal and life prognoses and incidence of renal replacement therapy. The effectiveness of intervention, nutrition therapy and exercise, in frail individuals is still not known. (Level: D, Grade: None) 1 3 CQ3: Is lipid lowering therapy recommended for elderly CKD patients aged more than 75 years? Statement: For elderly CKD patients aged 65-71 years, we propose that lipid lowering therapy (statin alone or a statin and ezetimibe combination) should be performed in elderly CKD patients aged 75 years or more since statins are effective for decreasing all -cause mortality and for primary or secondary prevention of CVD. (Level: C, Grade: 2) CQ4: Is renal biopsy recommended for elderly people aged more than 75 years?
Statement: There is no basis for contraindications of renal biopsy in elderly individuals aged > 75 years. There is also the possibility that the appropriate treatment can be determined based on renal biopsy. With respect to implementation, renal biopsy on elderly people should be introduced to experienced nephrologists and specialized medical institutions and their recommendations should be judged in consideration of renal function prognosis/life prognosis. (Level: D, Grade: None) CQ5: Could strict glycemic control (HbA1c < 7.0%) be recommended for CKD patients with DM aged more than 75 years?
Statement: CKD patients with DM aged ≥ 75 years should be recognized as being at risk of severe hypoglycemia and falls with strict glycemic therapy. We suggest that the target for glycemic control for elderly CKD patients should be decided individually depending on the health condition (age, cognitive function, physical function, comorbidity, risk of hypoglycemia, and time to live). (Level: D, Grade: None) CQ6: What is the optimal hemoglobin target range for anemic elderly patients (≥75 years) CKD patients? Statement: In anemic elderly patients (aged ≥ 75 years) with non-dialysis CKD, we suggest maintaining hemoglobin levels within the target range of 11-13 g/dL using erythropoietin-stimulating agents (ESAs) and/or iron supplementation. With respect to the mortality risk, the lower limit of the target range could be lowered to 9 g/dL. During the ESA therapy, clinical factors associated with resistance to ESAs should be removed to avoid use of high-dose ESAs. (Level: C, Grade: 2) CQ7: Are there any drugs to be especially attentive on drug usage for elderly CKD patients aged more than 75 years in daily clinical practice? Statement: Metabolic and excretion rates decline in elderly CKD patients aged more than 75 years, and attention must be paid to the control of the doses of RAS inhibitors, diuretics, vitamin D, and other drugs, which are frequently administered. Moreover, to avoid polypharmacy, we propose to check the medication notebook. (Level: D, Grade: 2) Chapter 13. Dialysis initiation CQ1: When should CKD patients be introduced to nephrologists to appropriately prepare for dialysis initiation?
Statement: It has been reported that the nephrologist's care of CKD patients before their dialysis initiation affects their selection of kidney transplantation or dialysis, increases the probability of success of operation of vascular access, and decreases early mortality after their dialysis initiation. When patients are at least CKD Stage G4, their consultation with nephrologists is proposed. (Level: C, Grade: 2) CQ2: To prevent the progression of kidney injury and late dialysis initiation, is patient education by various medical staff members recommended for CKD patients at CKD stage G3b or later? Statement: Because interdisciplinary team management including doctors and nurses may prolong dialysis initiation, patient education by various medical staff members is recommended for CKD patients at CKD stage G3b or later.
(Level: C, Grade: 2) CQ3: Should we perform CVD screening at the initiation of dialysis? Statement: There is no evidence to suggest that universal CVD screening is beneficial. However, as CKD is a wellknown risk factor for CVD, we suggest treatable CVD should be identified at least before the initiation of dialysis. Statement: Acetaminophen may be safer than NSAIDs for the short-term administration to patients with CKD. In particular, for elderly patients with decreased renal blood flow and GFR, the use of acetaminophen is proposed. However, even for acetaminophen, the safety of the long-term administration is not certain. (Level: D, Grade: 2) CQ2: Is it recommended to treat patients with an oral spherical carbon adsorbent? Statement: Although the therapeutic effect of an oral spherical carbon adsorbent on end-stage kidney disease (ESKD) or death in CKD patients is unclear, its treatment may be considered because there is a possibility of delaying CKD progression. (Level: C, Grade: 2) CQ3: Is it recommended to reduce treatment with antiviral drugs based on renal function in CKD patients suffering from herpesvirus infection? Statement: When administering antiviral drugs to CKD patients suffering from herpes simplex/herpes zoster virus infection, we propose designing drug administration based on evaluation of the renal function. In many cases, it may be expected that there will be a decrease in the adverse event occurrence by a drug administration design based on renal function, but even if only the dose is adjusted, it is necessary to pay close attention to the occurrence of adverse events (Level: D, Grade: 2). Statement: There is no direct evidence to demonstrate that screening for intracranial aneurysms is beneficial for lowering overall mortality or preventing rupture of aneurysms. Considering that prevalence of intracranial aneurysms in ADPKD patients is significantly higher than that in general population, however, their screening using MRI is suggested for ADPKD patients with a family history of intracranial aneurysms or subarachnoid hemorrhage. (Level: D, Grade: 2) CQ 2: Is tolvaptan recommended for ADPKD patients?
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Statement: We recommend using tolvaptan for autosomal dominant ADPKD patients with a total kidney volume of ≥ 750 mL and with an estimated creatinine clearance of ≥ 60 mL/min. We also recommend using tolvaptan for later-stage ADPKD patients with an eGFR of 25-60 mL/ min/1.73 m 2 to slow the increase in total kidney volume and the decline in kidney function. Safety and efficacy of tolvaptan in children have not been established yet. However, we recommend that patients refractory to initial treatment or having organ-threatening or life-threatening involvement be referred to, or managed in close collaboration with, an expert center and combined use of immunosuppressive therapy should be considered. (Level: D, Grade: 1)
